AACR: Adjuvant Atezolizumab + Bevacizumab Beneficial in Liver Cancer
TUESDAY, April 18, 2023 -- For patients with high-risk hepatocellular carcinoma (HCC), adjuvant therapy of atezolizumab with bevacizumab (atezo + bev) prolongs recurrence-free survival, according to a study presented at the annual meeting of the...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news
More News: Avastin | Cancer | Cancer & Oncology | Carcinoma | Hepatocellular Carcinoma | Liver | Liver Cancer | Pharmaceuticals | Study | Urology & Nephrology